BioCatalystWatch
PFEWorkspace / PFE / OverviewCompany library
Price
Market cap
Next catalystLater in 2026PADCEV (enfortumab vedotin-ejfv) · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

GLP-1 receptor

Upcoming / outlook

ELREXFIO monotherapy — MagnetisMM-5

BCMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PADCEV (enfortumab vedotin-ejfv)

Nectin-4

PF-07307405

OspA

Upcoming / outlook

  • Timing and evidence

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

JAK3 × TEC-family kinases

Upcoming / outlook

LITFULO — high-dose alopecia areata

JAK3 × TEC-family kinases

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

ELREXFIO monotherapy — MagnetisMM-5

BCMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PF-07307405

OspA

Upcoming / outlook

  • Timing and evidence

Other pipelines

PD-L1

PreINDP1P2P3FilingApproved

KRAS

PreINDP1P2P3FilingApproved

CDK4

PreINDP1P2P3FilingApproved
Berobenatide — monthly weight management / VESPER-6

GLP-1 receptor

PreINDP1P2P3FilingApproved

Partner / License out

PreINDP1P2P3FilingApproved

Approved / commercial

BCMA × CD3

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

BRAF V600E

Approved

PreINDP1P2P3FilingApproved

PARP

History / paused

PreINDP1P2P3FilingApproved

PARP

PreINDP1P2P3FilingApproved

P-selectin

PreINDP1P2P3FilingApproved
PF-06823859

IFN-β

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PFE SEC archive